P&U Files For Detrusitol In UK

6 April 1997

Pharmacia & Upjohn has filed for approval to market Detrusitol(tolterodine) tablets in the USA for the treatment of certain types and symptoms of urinary incontinence. The drug was submitted for European review with the regulatory authorities in Sweden in December 1996.

Tolterodine is one of a new wave of products which have moved into the revamped P&U pipeline since the merger of the two companies in 1995, and which also includes the antidepressant reboxetine and the glaucoma agent Xalatan (latanoprost), first launched in the USA in 1996.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight